Anti-human IgE protein single-domain antibody and application thereof

A single-domain antibody and protein technology, which is applied in the field of single-domain antibody against human IgE protein, can solve the problems of large side effects of treatment, and achieve the effects of low production cost, easy production control, and high adsorption capacity

Active Publication Date: 2020-11-03
GUANGZHOU KONCEN BIOSCI
View PDF13 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drug therapies are effective in the treatment of occasional allergic reactions, but have severe side effects in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human IgE protein single-domain antibody and application thereof
  • Anti-human IgE protein single-domain antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 Establishment of Alpaca Phage Antibody Library Binding to Human Immunoglobulin E (IgE)

[0041] Immunized alpaca with eukaryotic expressed human IgEcε2-4, collected peripheral blood mononuclear cells PBMC, extracted RNA, reverse transcribed into cDNA, amplified by PCR, digested with hindIII and NotI, and ligated to the phagemid vector pHIAT -1, transformed into Escherichia coli TG1 to form the original phage library. Add the helper phage M13KO7 to the TG1 strain that has grown to the logarithmic phase. After culturing overnight, collect the supernatant by centrifugation, precipitate the phage particles with PEG, resuspend the phage in PBS, and then filter and sterilize the phage through a 0.45um filter to obtain the phage VHH Antibody library, the library capacity is 4.8×10 13 .

Embodiment 2

[0042] Example 2 Screening of monoclonal phage antibodies

[0043] The titer determined by helper phage M13KO7 was 1×10 12 pfu / ml. TG1 was infected with helper phage M13KO7.

[0044](1) The first round of screening: Coat natural human IgE on the ELISA plate, 5 μg / well, overnight at 4°C, wash the plate 3 times; dissolve BSA with PBST to a concentration of 3%, 200 μL / well, block at 37°C for 2 hours, Wash the plate 3 times; add 100 μL of phage library solution to each well, incubate at 37°C for 2 hours, wash the plate 6 times; add 100 μL of glycine buffer solution (gly-HCL) to each well and shake gently for 10 min at room temperature, suck out the eluate, and add 80 μL Neutralize with Tris-HCl buffer. Take 10 μL of the eluate to measure the titer, and add the rest to 5 mL of TG1 strain that has grown to the logarithmic phase, infect at 37 ° C for 30 min, add preheated 2×YT medium to a total volume of 10 mL, 37 ° C, 250 rpm, 30 min, Add ampicillin to a final concentration of 1...

Embodiment 3

[0049] Example 3 In vitro recombinant expression and antibody purification

[0050] The gene sequence whose amino acid sequence is shown as SEQ ID NO.1 was transferred into PET28 plasmid through restriction sites NcoI and XhoI, and expressed in Escherichia coli BL21(DE3). After expanded culture with LB medium containing 70 μg / mL kanamycin, the bacteria were collected, sonicated (on for 5 s, off for 10 s, working time 20 min), centrifuged at 10,000 rpm for 10 min, and the supernatant was collected. The his tag was used for purification with a nickel ion chelating filler, and the eluted peak was collected to obtain the alpaca single domain antibody SD1. The expression level of the single domain antibody SD1 was determined to be 30 mg / L.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Titeraaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of blood purification, in particular to an anti-human IgE protein single-domain antibody and an application thereof. The structural general formula of the amino acidsequence of the single-domain antibody is shown as MDVQLQESGG-X1-LSC-X2-GRFTIS-X3-GQTQVTVVSS, wherein X1 is an amino acid sequence containing 1-9 amino acids, X2 is an amino acid sequence containing1-43 amino acids, and X3 is an amino acid sequence containing 1-38 amino acids. According to the invention, the soluble single-domain antibody capable of being expressed by prokaryotic or eukaryotic is screened by a phage display technology, and the production cost is low. An immunoadsorbent synthesized after the obtained single-domain antibody is coupled to a solid-phase carrier is high in humanIgE adsorption capacity and good in specificity; and the non-specific adsorption to human IgG is relatively low. The anti-human IgE protein single-domain antibody provided by the invention provides anew c selection for treating allergic diseases.

Description

technical field [0001] The invention relates to the field of blood purification, in particular to an anti-human IgE protein single-domain antibody and its application. Background technique [0002] Hypersensitivity has an enormous prevalence, affecting more than 25% of the world's total population. Among them, type I allergy, also known as immediate allergic reaction or anaphylaxis, is an immune system disease caused by IgE binding to high-affinity receptors on the surface of mast cells and basophils, such as clinically common allergic reactions Asthma, allergic urticaria, allergic dermatitis, allergic rhinitis and anaphylactic shock caused by penicillin, etc. When an allergic reaction occurs, the IgE concentration in the patient's body reaches more than 10 times the normal value, especially the concentration of allergen-specific IgE can reach about 1000 times the normal value (GOULD H J, SUTTON B J et al. 2003). [0003] At present, drug therapy is the main method for the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/42B01J20/26B01J20/30A61K39/395A61P37/08A61P11/06A61P11/02A61P11/00A61P17/00
CPCA61P11/00A61P11/02A61P11/06A61P17/00A61P37/08B01J20/265C07K16/005C07K16/4291C07K2317/22C07K2317/569C07K2317/76
Inventor 张海珍杨正根陈臻毅余波光牛月伟陈校园
Owner GUANGZHOU KONCEN BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products